Director Dealings / Market Share Sale and Purchase

Oxford, UK - 19 September 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 18 September 2017 Tim Watts, a director, exercised options over 1,182,813 ordinary shares of 1p each ("Ordinary Shares") in the Company. 

246,072 of these options were granted under the Company's 2007 Long Term Incentive Plan and were exercisable at 1p.  936,741of these options were granted under the Company's 2015 Deferred Bonus Plan and were nil cost options.

Following the exercise Mr Watts holds 17,181,767 ordinary shares of 1p each ("Ordinary Shares") in the Company, 0.55% of the Company's issued share capital.

The issued share capital of the Company after this exercise is 3,106,253,317 1p ordinary shares.

-Ends-

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.